Claryx

Hospitals have always treated infection control as a rear-guard action. A patient tests positive, the infection prevention team scrambles to trace contacts, cultures are taken, and maybe—days later—the source is found. By then, the pathogen has often moved on. Claryx, a New York-based biotech startup, is trying to flip that sequence entirely. Instead of waiting for the patient to become the signal, it continuously samples the hospital itself—air, sinks, wastewater, high-touch surfaces—and sequences everything to build a genomic baseline of the building. When a patient does get infected, Claryx sequences that infection and matches it against the environmental data using its CloneLink platform. The result is a strain-level connection that tells the infection prevention team not just that an infection exists, but where it came from, how it's spreading, and whether the intervention actually worked.

The pitch is bold: a "hospital immune system" that detects, traces, recommends, and confirms—all within 72 hours. It's a fundamental reframing of what hospital surveillance can be, and it comes with a price tag and a service model that will test whether hospitals are ready to outsource their infection intelligence.

The hospital as a patient

Claryx's core insight is that the hospital environment is not a passive backdrop to patient care—it's an active reservoir of pathogens. The CDC estimates that 1 in 38 US hospital patients has an infection they developed while in the hospital on any given day. That's a staggering number, and it's the problem Claryx is built to solve. But the company's approach is less about treating the individual patient and more about treating the hospital as a patient itself.

This is a subtle but crucial shift. Traditional infection prevention is reactive: a patient gets sick, the lab runs a culture, and the IPC team investigates. Claryx inverts that logic. By continuously sampling the environment—the air in the ICU, the sink drains, the scopes, the door handles—it creates a living map of what's thriving in the building. When a patient infection occurs, Claryx can immediately check whether that strain is already present in the environment, and if so, where. This turns the hospital into a monitored organism, where every surface is a potential data point.

The company's founders, Canadian brothers Kurt and Dirk Hackenberger, are betting that this environmental layer is the missing piece in infection control. And they're starting in the US because, as they've said, it's simpler to sell in the private system. That's a telling strategic choice, and it speaks to the business model they're building.

AeroScan and the missing environmental layer

Claryx's hardware-software combo is called AeroScan. It's a continuous air sampler that sits in high-risk areas like ICUs, emergency departments, and transplant wards. But AeroScan is just the visible tip. The company also samples wet reservoirs—sinks, wastewater—and high-touch surfaces, sending everything to its lab for metagenomic sequencing.

What makes this different from standard environmental testing is the scale and the resolution. Traditional testing might look for specific pathogens—MRSA, C. diff, VRE—using culture or PCR. Claryx sequences everything, which means it can detect not just known pathogens but also novel or unexpected ones. And it does this continuously, building a baseline over time. A single positive swab from a sink drain is a data point; a continuous genomic stream is a pattern.

The company claims its breakthrough IP cuts certain sequencing costs over twentyfold, which is what makes this continuous surveillance economically feasible. That's a critical claim, because the cost of sequencing has historically been the barrier to this kind of approach. If Claryx can genuinely deliver whole-environment metagenomics at a fraction of the usual cost, it removes the main objection to continuous monitoring.

CloneLink: matching genomes, not just symptoms

The heart of Claryx's platform is CloneLink, the software that compares clinical genomes and environmental metagenomes at the strain level. When a patient's infection matches an environmental sample, CloneLink flags it as a likely transmission event. This is the difference between correlation and causation: two patients with MRSA might be coincidental, but if the strain in patient A's blood is genetically identical to the strain in the sink drain in room B, that's a connection worth acting on.

Claryx claims 1-to-1 attributable resolution—the level of specificity needed to tell coincidence from transmission. This is where the science gets serious. Standard infection control often relies on epidemiological links (patient A was in the same room as patient B) or phenotypic tests (both are MRSA). Genomic strain-level matching is far more precise, and it's the kind of evidence that can justify expensive interventions like deep cleaning, equipment replacement, or ward closures.

The company cites a prospective study showing that 96% of transmission routes acted on were contained at the source using genomic intelligence. That's a powerful number, though it's from a study Claryx didn't conduct. Still, it points to the potential of the approach.

The 72-hour loop that ends guesswork

Claryx's value proposition is not just detection—it's the full loop: detect, trace, recommend, confirm. The company says it can provide strain-level linkage within 72 hours, and then verify whether the intervention worked. This is a significant improvement over traditional methods, which can take days or weeks to culture and confirm.

The speed matters because every day an infection goes unconfirmed is a day it keeps spreading. Claryx's continuous sampling means the environmental baseline is always up to date, so when a patient tests positive, the comparison can happen immediately. The company claims intervention speed increases by over 15x, which is a dramatic claim but plausible given the shift from reactive culturing to continuous genomic surveillance.

For infection preventionists, this is the difference between chasing coincidences and stopping outbreaks. For infectious disease physicians, it's the ability to validate intuition with hard data. Claryx's website quotes Russell Kerbel, MD MBA, Medical Director of Sepsis at UCLA Health: "Every case of sepsis begins as an infection. Faster treatment saves lives, but the next frontier is identifying outbreaks earlier, preventing transmission, and delivering targeted antimicrobial therapy before patients ever become septic." That's the promise Claryx is selling.

Why the CFO cares about a tenth of a day

Claryx's pitch to hospital administrators is as much about money as it is about safety. The company cites that every hospital-acquired infection adds an average of ~7.8 days to a patient's stay. On razor-thin margins, those extra days are often absorbed at cost with no additional reimbursement. Claryx's model shows that reducing average length of stay by just 2% can produce millions in profit.

The math is compelling: at a 526-bed hospital, cutting a tenth of a day off length of stay frees beds and generates up to $7.0 million in incremental profit. That's before counting the avoided cost of treating the infections themselves. For a CFO, this is not just a patient safety issue—it's a revenue opportunity.

Claryx is careful to frame itself as a value-add, not a cost center. The managed-service model means the hospital doesn't have to buy sequencing equipment or hire bioinformaticians. Claryx runs the sampling, sequencing, and analysis, and delivers a signal. That's a compelling pitch for resource-constrained IPC teams.

The managed-service bet: selling outcomes, not devices

Claryx is not selling a box. It's selling a service: fully managed, from sample to signal. The company sends its own team to sample the environment, runs the sequencing at its own lab, and delivers actionable alerts through CloneLink. This is a deliberate strategic choice, and it's a bet that hospitals would rather buy outcomes than infrastructure.

The bet is reasonable. Hospital labs are already stretched, and metagenomic sequencing is a specialized skill. But it also means Claryx carries the operational burden—and the risk. If the service doesn't deliver, the hospital can walk away. That's a high bar, but it's also the kind of commitment that builds trust.

The company has raised $3.5 million in pre-seed funding led by Outlander, which suggests early investor confidence. But the real test will be whether pilot hospitals see the 96% containment rate and the 15x speed improvement in practice. The founders are starting in the US because the private system is simpler to sell to, but the long-term opportunity is global.

Claryx's vision is ambitious: to give every hospital an immune system. It's a compelling metaphor, and the technology is real. But the hardest part isn't the sequencing—it's convincing risk-averse health systems to trust a new kind of intelligence. If Claryx can do that, it won't just be a product. It'll be a new standard of care.